Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
OBJECTIVE
Cardiovascular disease is a leading cause of death in Eastern Europe. Few studies on cholesterol goal achievement have been conducted in Hungarian clinical settings. This study set out to evaluate lipid-modifying therapy practices and their effects on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) goal attainment in Hungarian patients with coronary heart disease (CHD), CHD risk equivalents, or >or=2 coronary risk factors.


METHODS
This multicentre observational study involved patients receiving lipid-modifying therapy who were under the care of general practitioners (n = 300) or specialists (n = 140). Physician questionnaires were used to collect data on baseline patient characteristics, including laboratory parameters. Using validated cardiovascular risk assessment measures, patients were stratified into high-risk (10-year absolute coronary risk >20%; n = 367) and lower risk groups (n = 73). Cholesterol goals were TC <4.5 mmol/L (<175 mg/dL) and LDL-C <2.5 mmol/L (<100 mg/dL) for the high-risk group and TC <5.0 mmol/L (<193 mg/dL) and LDL-C <3.0 mmol/L (<117 mg/dL) for those at lower risk.


RESULTS
Among 440 patients (n = 312 with CHD or CHD risk equivalents), 374 (85%) were initiated on HMG-CoA reductase inhibitors (statin monotherapy), 44 (10%) received fibric acid derivatives and 22 (5%) received combination regimens. Although >50% of patients needed >35% TC lowering to reach goal, <10% of patients received high or very high potency lipid-modifying regimens or combination regimens initially. A total of 116 (26.4%) patients achieved their TC goals after >/=1 year of treatment, including 27.9% of patients with CHD/risk equivalents and 22.7% of those with risk factors only. Sixty-six (15%) patients achieved goal on initial lipid-modifying regimens, while a further 50 (11.4%) achieved goal following treatment changes, including upward dosage adjustments.


CONCLUSIONS
Approximately 74% of Hungarian patients receiving lipid-modifying therapy in our study did not achieve cholesterol goals. The proportion of patients realising their TC goals was higher in those treated by specialists but still did not exceed one-third.
Paragh
György
G
First Department of Medicine, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary. paragh@internal.med.unideb.hu
Márk
Lászlo
L
Zámolyi
Károly
K
Pados
Gyula
G
Ofner
Péter
P
D000368:Aged; D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000097:blood / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood*; D002995:Clofibric Acid / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D006814:Hungary; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002995:Clofibric Acid; D002784:Cholesterol
Clin Chem. 1972 Jun;18(6):499-502
4337382
Arch Intern Med. 1998 Jun 8;158(11):1238-44
9625403
J Lipid Res. 1979 Mar;20(3):389-98
109556
Am J Cardiol. 2002 Nov 15;90(10):1084-91
12423708
Diabetes Nutr Metab. 2000 Oct;13(5):263-8
11105968
N Engl J Med. 2006 Aug 10;355(6):549-59
16899775
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132-7
15928087
Eur Heart J. 1997 Oct;18(10):1569-82
9347267
BMJ. 2005 Jul 23;331(7510):208-10
16037458
JAMA. 2004 Sep 15;292(11):1307-16
15337732
Eur Heart J. 2001 Apr;22(7):554-72
11259143
Curr Med Res Opin. 2007 Apr;23(4):767-75
17407633
Prog Cardiovasc Nurs. 2005 Spring;20(2):70-6
15886550
Am J Cardiol. 2004 Jun 15;93(12):1487-94
15194018
Pharmacoeconomics. 2004;22 Suppl 3:1-12
15669149
Arch Intern Med. 2000 Feb 28;160(4):459-67
10695686
Lancet. 2001 Mar 31;357(9261):995-1001
11293642
JAMA. 2004 Mar 3;291(9):1071-80
14996776
Int J Clin Pract. 2005 Jun;59(6):619-27
15924587
Orv Hetil. 2003 Dec 7;144(49):2399-404
14725205
Mayo Clin Proc. 2004 May;79(5):620-9
15132403
Circulation. 2002 Dec 17;106(25):3143-421
12485966
Am J Cardiol. 1999 May 1;83(9):1303-7
10235085
Arch Intern Med. 2005 Apr 25;165(8):929-35
15851646
Circulation. 2002 Aug 20;106(8):1024-8
12186811
Am J Med. 1996 Jun;100(6):605-10
8678079
Am J Cardiovasc Drugs. 2006;6(2):121-8
16555865
Am J Med. 2005 Dec;118 Suppl 12A:36-41
16356806
Curr Med Res Opin. 2004 Jul;20(7):1025-33
15265247
Am J Cardiol. 2002 Mar 15;89(6):672-8
11897208
Orv Hetil. 2003 Mar 9;144(10):451-60
12687794
Int J Cardiol. 2005 Jul 10;102(2):327-32
15982505
Arch Intern Med. 2004 Nov 22;164(21):2343-8
15557413
Curr Med Res Opin. 2002;18(4):220-8
12201623
Circulation. 2006 Feb 14;113(6):e85-151
16407573
Mayo Clin Proc. 2005 May;80(5):587-95
15887425
N Engl J Med. 2005 Apr 7;352(14):1425-35
15755765
Am J Cardiol. 2007 Mar 1;99(5):673-80
17317370
Eur Heart J. 2002 Aug;23(15):1190-201
12127921
Acta Cardiol. 2001 Apr;56(2):109-14
11357922
J Am Coll Cardiol. 2002 Dec 18;40(12):2125-34
12505224
Circulation. 2000 Jan 18;101(2):207-13
10637210
Int J Clin Pract. 2004 Jul;58(7):653-8
15311720
Curr Med Res Opin. 2005 Apr;21(4):571-8
15899106
Am Heart J. 2005 Mar;149(3):464-73
15864235
Curr Med Res Opin. 2005 Sep;21(9):1389-99
16197657
Br J Clin Pharmacol. 2005 Apr;59(4):456-63
15801941
Am J Med. 1996 Feb;100(2):197-204
8629655
J Manag Care Pharm. 2004 May-Jun;10(3):251-8
15228376
JAMA. 2005 Nov 16;294(19):2437-45
16287954
Curr Med Res Opin. 2006 Oct;22(10):2041-53
17022864
Circulation. 2003 May 20;107(19):2409-15
12719279
Circulation. 2004 Jul 13;110(2):227-39
15249516
Mayo Clin Proc. 2006 Dec;81(12):1579-88
17165637
Am Heart J. 2004 Sep;148(3):447-55
15389231
J Fam Pract. 1998 Nov;47(5):349-56
9834769
N Engl J Med. 2004 Apr 8;350(15):1495-504
15007110
JAMA. 2006 Dec 6;296(21):2563-71
17101639
Eur J Cardiovasc Prev Rehabil. 2005 Feb;12(1):37-45
15703504
Am J Cardiol. 2002 Feb 1;89(3):268-75
11809427
Int J Clin Pract. 2005 Dec;59(12):1377-86
16351668
Arch Intern Med. 2002 Apr 8;162(7):797-804
11926854
Curr Med Res Opin. 2000;16(3):208-19
11191012
BMJ. 2005 Apr 30;330(7498):991
15820966
Am J Cardiol. 2003 Jul 1;92(1):79-81
12842255
Pharmacoeconomics. 2004;22 Suppl 3:13-23
15669150